Related Experiment Video
Updated: Nov 4, 2025
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians
Gerald F Watts1,2, David R Sullivan3,4, David L Hare5,6
1School of Medicine, University of Western Australia, Perth, Western Australia, Australia.
Insights
New clinical guidelines offer improved detection, diagnosis, and management strategies for familial hypercholesterolaemia (FH), a genetic condition causing premature heart disease. These recommendations emphasize risk stratification and advanced LDL-cholesterol-lowering therapies for better patient outcomes.
Area of Science:
- Cardiology
- Genetics
- Public Health
Background:
- Familial hypercholesterolaemia (FH) is a prevalent, inherited condition leading to premature coronary artery disease.
- Effective management of FH is crucial for preventing cardiovascular events.
Purpose of the Study:
- To present updated clinical practice recommendations for the comprehensive care of individuals with FH.
- To guide practitioners in the detection, diagnosis, assessment, and management of FH across all age groups.
Main Methods:
- Development of core recommendations for FH management, incorporating risk stratification.
- Inclusion of lifestyle modifications and pharmacotherapies, including statins, ezetimibe, and PCSK9 inhibitors.
- Emphasis on clinical judgment and shared decision-making in patient care.
Main Results:
- The recommendations cover the management of adults, children, and adolescents with FH.
- Integration of genetic testing, PCSK9 inhibitors, and national genomics policies facilitates adoption.
- A strategic implementation plan is necessary to ensure widespread benefit for FH families.
Conclusions:
- Updated recommendations provide a framework for enhanced FH care.
- Multifaceted management strategies are essential for mitigating cardiovascular risk in FH patients.
- Successful implementation requires a coordinated approach involving healthcare providers, policymakers, and patients.
Abstract:
Familial hypercholesterolaemia (FH) is a common, heritable and preventable cause of premature coronary artery disease. New clinical practice recommendations are presented to assist practitioners in enhancing the care of all patients with FH. Core recommendations are made on the detection, diagnosis, assessment and management of adults, children and adolescents with FH. Management is under-pinned by the precepts of risk stratification, adherence to healthy lifestyles, treatment of non-cholesterol risk factors and appropriate use of low-density lipoprotein (LDL)-cholesterol-lowering therapies including statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The recommendations need to be utilised using judicious clinical judgement and shared decision-making with patients and families. New government-funded schemes for genetic testing and use of PCSK9 inhibitors, as well as the National Health Genomics Policy Framework, will enable adoption of the recommendations. However, a comprehensive implementation science and practice strategy is required to ensure that the guidance translates into benefit for all families with FH.
Related Concept Videos
01:26Atherosclerosis III: Management
01:18Lipids: Dietary Sources and Requirements
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:23Atherosclerosis IV: Nursing Management
01:26Coronary Artery Disease IV: Preventive Measures
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents